Trump disclosures show Eli Lilly share buys as GLP-1 access expanded
Filings list seven acquisitions of Lilly stock worth up to $680,000 between 6 January and the end of March 2026.
DO
By Daniel Okafor · Regulatory Correspondent
May 19 03:00 ETSource: The Guardian
The wire
- 01Ethics filings released last week show trades on the president's behalf worth a cumulative $220m to about $750m in the first quarter of 2026, including the Lilly purchases flagged by KFF Health News.
- 02Over the same window federal agencies moved to expand GLP-1 access, including a CMS pilot covering Lilly's Foundayo and Zepbound KwikPen for Medicare patients and the TrumpRx site pointing users to LillyDirect.
- 03The Trump Organization says holdings sit in fully discretionary third-party accounts and the president plays no role in stock selection; Lilly, HHS and the White House did not immediately comment.
From the source
Read at theguardian.comEli Lilly shares bought on Trump’s behalf as his policies benefited drug firm
Filings reveal $220m to $750m in trades on US president’s behalf in first quarter of 2026, including securities linked to largest US companies